Lithium vs. Valproate in Residual Schizophrenia: Case Safety Signal
A 2026 case report described valproate 800 mg/day improving agitation in residual-phase treatment-resistant schizophrenia but being followed by hypoglycemia and pancytopenia; after discontinuation, lithium 600 mg/day at 0.8 mEq/L was associated with BPRS improvement from 80 to 64.1 The calibrated read is mixed: valproate looked behaviorally useful in 1 patient, but the safety signal was …